Puchner T C, Kugathasan S, Kelly K J, Binion D G
Department of Medicine, Digestive Disease Center, Children's Hospital of Wisconsin, Medical College of Wisconsin, Milwaukee, USA.
Inflamm Bowel Dis. 2001 Feb;7(1):34-7. doi: 10.1097/00054725-200102000-00005.
Infusion of the antitumor necrosis factor-alpha chimeric monoclonal antibody infliximab is highly effective in the treatment of refractory and fistulizing Crohn's disease (CD), but can be associated with the development of severe allergic reactions during retreatment, precluding further use of the medication. We present two CD patients (one adult and one child) with a history of anaphylactic/anaphylactoid reactions to retreatment with infliximab who subsequently underwent successful desensitization and therapeutic infusion using parenteral dose escalation in an intensive care unit setting.
输注抗肿瘤坏死因子-α嵌合单克隆抗体英夫利昔单抗在治疗难治性和瘘管性克罗恩病（CD）方面非常有效，但在再次治疗期间可能会出现严重过敏反应，从而无法继续使用该药物。我们报告了两名CD患者（一名成人和一名儿童），他们在再次使用英夫利昔单抗治疗时发生过过敏/类过敏反应，随后在重症监护病房环境中通过肠外剂量递增成功进行了脱敏和治疗性输注。
